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Abstract C57BL/6 mice were infected with Neospora
caninum tachyzoites during pregnancy, yielding a transpla-
cental infection of developing fetuses. Subsequently, con-
genitally infected newborn mice were treated either once or
three times with toltrazuril (or placebo) at a concentration of
31.25 mg compound per kg body weight. Both toltrazuril
and placebo treatment had no negative effect on newborns,
as noninfected treated pups developed normally without
differences in mortality and morbidity to matching non-
treated control animals. Already one application of toltrazuril
was significantly (p<0.01) able to delay the outbreak of
neosporosis in newborn mice, when compared to placebo-
treated infected controls. We found significantly higher
proportion of surviving newborns in one-time-toltrazuril-
treated and three-time-toltrazuril-treated groups (34% and
54%, respectively) when compared to one-time-placebo-
treated and three-time-placebo-treated groups (14% and
30%, respectively). There was no significant difference (p=
0.2) in the proportion of surviving pups between one-time-
toltrazuril and three-time-toltrazuril treatment. However, the
number of diseased and Neospora-positive pups (46% and
47%, respectively) was markedly reduced after three-time-
toltrazuril treatment compared to all other groups. Three-
time-treatment also resulted in the highest antibody (IgG,
IgG2a) response. Pharmacokinetic analyses using individual
serum samples revealed that, although toltrazuril was
absorbed and metabolized to toltrazuril sulfone by newborn
mice, medicated animals exhibited an unexpected rapid turn-
over (half-life time) of the compound. Toltrazuril and the
metabolite were also found in brain tissues, indicating that
passage of the blood–brain barrier occurred. In conclusion,
we could show that three times treatment with toltrazuril had
a high impact on the course of infection in congenitally N.
caninum-infected newborn mice.
Introduction
The main problems associated with Neospora caninum and
the corresponding disease, neosporosis, are (1) abortion in
cattle (Dubey 2003), causing serious veterinary health
issues and economic losses within livestock production
(Hemphill and Gottstein 2000; Dubey et al. 2007), and (2)
neuromuscular disease in dogs (Dubey 2003).
The need for the development of effective prophylactic
or metaphylactic measures against bovine neosporosis has
been widely addressed and discussed (Liddell et al. 1999;
Gottstein et al. 2001; Innes et al. 2002; Kritzner et al. 2002;
Häsler et al. 2006a, b). Although there are successful
experimental vaccination approaches to prevent cerebral
neosporosis (Cannas et al. 2003a, b; Debache et al. 2008) or
vertical transmission (Nishikawa et al. 2001) in mice, there
are currently no vaccines available to protect cattle from
abortion (Andrianarivo et al. 2000; Innes and Vermeulen
2006).
Chemotherapy is being discussed as an interesting
alternative to the vaccination strategy (Ortega et al. 2007).
So far, a wide range of compounds have been tested in cell
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culture-based assays and some pharmacologically active
compounds, including lasalocid, monensin, piritrexim,
pyrimethamine, and trimethoprim, were found to exhibit
parasiticidal activity against N. caninum (Lindsay and
Dubey 1989; Lindsay et al. 1994). More recently, it was
reported that nitazoxanide (NTZ) and a series of NTZ
derivatives efficiently inhibited N. caninum proliferation in
vitro (Esposito et al. 2005; Esposito et al. 2007), and new
generation diaminidines were shown to exhibit in vitro
parasiticidal activity against N. caninum at the submicro-
molar level (Leepin et al. 2008). In vivo studies showed
that oral drug treatment of Neospora-infected mice with
sulfadiazine and amprolium was rather ineffective (Lindsay
and Dubey 1990).
Toltrazuril, a symmetric triazinone derivative, was
shown to exhibit anticoccidial activity against cyst-forming
and noncyst-forming coccidian parasites (Haberkorn 1996).
Toltrazuril is a weak acid compound (pKa=6.8) with high
lipid solubility. Pharmacokinetic studies in horses revealed
that toltrazuril and its metabolites penetrated the blood–
brain barrier (Furr and Kennedy 2000). The effect(s) of
toltrazuril on the fine structure and multiplication of N.
caninum were studied in cell culture demonstrating lethal
damage in N. caninum tachyzoites (Darius et al. 2004a, b).
The effect of toltrazuril on parasite survival after long-term
treatments in cell culture, assessed by quantitative reverse
transcription polymerase chain reaction, revealed a parasit-
icidal activity starting after a continuous 14-day treatment
(Strohbusch et al. 2008). In the murine model of experi-
mental N. caninum infection, toltrazuril treatment prevented
severe clinical signs and formation of cerebral lesions
(Gottstein et al. 2001; Darius et al. 2004a, b). However, an
efficient metaphylaxis required at least a T cell-mediated
immunological support in mice (Ammann et al. 2004). It
was also reported that toltrazuril treatment of an acute N.
caninum infection—induced during pregnancy in mice—
resulted in a significant reduction of fetal losses (Gottstein
et al. 2005). Furthermore, initially explorative approaches
indicated a basic effectiveness of toltrazuril and its major
metabolite, ponazuril, against experimental N. caninum
infection in calves (Kritzner et al. 2002; Härdi et al. 2006).
In this study, we used the mouse model to determine
whether treatment of neonates with toltrazuril has any
effect, positive or negative, on the outcome of infection and
disease.
Materials and methods
Tissue culture media, biochemicals, and drugs
If not otherwise stated, all tissue culture media were
purchased from Gibco-BRL (Basel, Switzerland) and
biochemical reagents were from Sigma (St. Louis, MO,
USA). Toltrazuril and the corresponding placebo formulat-
ed for oral application were provided by Bayer HealthCare
AG (Germany), stock solutions were diluted with water and
used immediately.
Tissue culture and parasite purification
Cultures of Vero cells were maintained in RPMI 1640
medium (Gibco-BRL, Basel, Switzerland) supplemented
with 5% fetal calf serum (FCS), 4 mM L-glutamine,
100 U/mL penicillin G, 100 μg/mL streptomycin, and
0.25 μg/mL amphotericin B at 37°C with 5% CO2.
Cultures were trypsinized at least once a week. N.
caninum (Nc-1 isolate) tachyzoites were maintained in
Vero cell monolayer cultures, during which time FCS was
replaced with immunoglobulin G-free horse serum.
Tachyzoites were harvested when they were still intracel-
lular by trypsinization of infected Vero cells followed by
repeated passage through a 25-gauge needle. Host cell
debris were removed from parasites by separation on
Sephadex-G25 columns as previously described (Hemphill
et al. 1996). The tachyzoites were counted using a Neubauer
chamber and parasite numbers were adjusted by adding
RPMI medium as appropriate for experimental infection.
Mice, infection, treatment, and euthanasia
Twenty-eight pregnant wild-type C57BL/6 mice were pur-
chased from Charles River Laboratories (Sulzfeld, Germany).
Infection with N. caninum or mock infection with medium
(control) was carried out at gestation day (GD) 13. Mice
were maintained under conventional day/night cycle housing
conditions as required by the animal welfare legislation of
the Swiss Veterinary Office. Special food mix for breeding
mice and water were provided ad libitum. For N. caninum
infection, 18 mice were randomly selected and intraperito-
neally (i.p.) inoculated with 6×105 live Nc-1 tachyzoites
suspended in 200 μL RPMI medium. Matching control mice
(n=3) received 200 μL medium without parasites. All mice
were individually housed and checked daily for clinical
signs, abortion, or preterm birth. Day of delivery was
designated as day 0. Newborn mice were counted and daily
checked for survival and health status. Infected dams and
corresponding litters were randomly selected and divided
into four treatment groups (groups C–F). Neonates from
infected dams were treated either once (group C) or three
times (group D) with toltrazuril or once (group E) or three
times (group F) with placebo, respectively. Newborns from
uninfected control mice were either treated three times with
toltrazuril (group A) or placebo (group B).
In a parallel set of control experiments designed to
temporally monitor plasma levels of toltrazuril (pharmaco-
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kinetic study), seven pregnant C57BL/6 mice were used
(group G).
For any treated animal, the first dose (toltrazuril at a
concentration of 31.25 mg/kg body weight [bw]) was
administered at days 3 and 4 of age, respectively. The
treatment was done orally using a pipette, taking
advantage of the sucking effect of newborns. Treatments
were repeated identically at days 14 and 29 with
62.5 mg/kg bw, if applicable. For groups A–F, cages
were daily checked and dead pups, if found, were
removed as soon as possible. Pups and dams with
clinical signs were euthanized immediately by CO2
inhalation. All other dams were separated from pups and
euthanized at day 28 (33 days post infection [dpi]),
remaining pups were euthanized between days 64 and
100 of age. From all animals, pieces of brain, lung, heart,
and liver were collected and stored at −20°C prior to DNA
extraction. If possible, blood was taken for enzyme-linked
immunosorbent assay (ELISA). For group G, three to five
newborn mice were randomly selected before the first,
second, and third treatment and at days 2, 5, 12, 17, 27,
32, and 45 posttreatment (counted after the first treatment
onwards). Pups were killed and serum and brain tissues
samples were frozen at −20°C prior to evaluation of
toltrazuril and toltrazuril sulfone (major metabolite)
concentration.
Vertical transmission
The proportion of vertical transmission from infected dams
to fetuses was calculated retrospectively. All pups that died
before initiation of treatment and pups from infected and
placebo-treated groups (E, F) were tested for Neospora
infection by conventional polymerase chain reaction (PCR)
(see below). The number of PCR-positive pups was divided
by the overall number of pups from these groups.
DNA extraction
DNA purification was performed using the DNeasy
blood and tissue kit (Qiagen, Basel, Switzerland)
according to the standard protocol suitable for animal
tissues. Frozen organs were equilibrated to room
temperature and then lysed overnight at 56°C in ATL
buffer containing Proteinase K (12 mLAU/mL). DNA
was eluted in 100 μL AE buffer, boiled at 95°C for
3 min, and frozen at −80°C prior to PCR.
Conventional PCR
Detection of parasite-specific DNA by PCR was done as
previously described (Müller et al. 1996) with N. caninum-
specific primers Np21plus and Np6plus.
Serology
Mouse serum samples were analyzed for the presence of
antibodies against Nc-1 antigen by ELISA using the same
somatic antigen as previously described (Eperon et al.
1999). Alkaline phosphate-conjugated goat antimouse IgG
(Promega, Duebendorf, Switzerland), anti-IgG1, or anti-
IgG2a (both from Southern Biotechnology Associates,
Birmingham, AL, USA) were used as second antibody
(conjugate). Absorbance was measured at 405 nm (A405,
reference filter 630 nm) using a Dynatech MR 7000 ELISA
reader and the corresponding Dynatech Biocalc software
(Dynatech, Embrach, Switzerland). The threshold value
arbitrarily discriminating between “positive” and “nega-
tive” (cut-off) was defined by adding three standard
deviations to the mean A405 value of the serum samples
from noninfected and nontreated control mice.
Toltrazuril and toltrazuril sulfone concentration
Toltrazuril and toltrazuril sulfone concentrations were out-
sourced and thus determined at the laboratory for Animal
Health (Bayer CropScience AG, BCS-D-ROCS, Monheim
am Rhein, Germany). Serum samples were deproteinized
with acetonitrile. Brain samples were extracted by homog-
enization with acetonitrile and water. After centrifugation,
the quantitative determination was performed directly from
the raw extract by high-performance liquid chromatography
with detection by tandem mass spectrometry. The lower
limit of detection was 0.025 mg/L for serum and 0.050 mg/L
for brain tissue.
Statistical analyses
Comparisons of the IgG1 and IgG2a response in infected
dams, number of cannibalized pups in noninfected and
infected groups, as well as toltrazuril and toltrazuril sulfone
concentrations in serum and brain samples were done using
the Student’s t test. Specific antibody responses (IgG, IgG1,
and IgG2a) of the pups and the outbreak of the disease were
analyzed using one-way analysis of variance (ANOVA). A
nonparametric Kruskal–Wallis test was used wherever the
distributional assumptions required for an ANOVA were
felt to be unrealistic. When statistical differences were
found, a nonparametric multiple comparison test was used
to examine all possible pairwise comparisons. Survival
curves were calculated using the Kaplan–Meier survival
statistic and differences between groups were determined
using the log-rank survival tests. Pups that died or became
ill during the experiment were designated as failed, while
healthy pups were designated as censored. Differences
between the numbers of diseased or PCR-positive pups
were analyzed by the chi-square test. A value of p<0.05
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was considered statistically significant. All statistical
analyses were carried out using the NCSS software version
2001 (NCSS, Kaysville, UT, USA).
Results
Infection of the dams and outcome of pregnancy
After infection at GD 13, none of control (n=3) and
infected (n=18) dams showed abortion. All dams gave birth
between GD 17 and 19. There was no difference (p=0.2) in
the number of pups per litter between uninfected and
infected animals (Table 1). Three out of 18 infected dams
became sick at 19, 21, and 26 dpi, respectively. These three
mice and also dams from which all pups died before the
end of the lactation period (n=4; 6, 11, 13, 21 dpi) were
killed. The remaining infected (n=11) and control (n=3)
dams were killed at the end of the weaning period (33 dpi
corresponding to 28 days after delivery). All dams yielded
positive (conventional) PCR findings for Neospora DNA in
the brain (data not shown). Furthermore, all 18 infected
dams were seropositive at necropsy. Investigation for
immunoglobulin subclasses by ELISA revealed a signifi-
cantly higher level of IgG2a than of IgG1 (p=0.006) in
infected dams (Fig. 1), indicating a rather Th1-oriented
immune response after infection at GD 13. Uninfected
control dams were all PCR-negative and N. caninum
ELISA seronegative.
Treatment and subsequent proportion of surviving newborn
mice
All treated pups were checked for their health status on a daily
basis. Pups cannibalized by the dam were excluded from
further investigations. There was no significant difference in
the number of cannibalized pups from uninfected or infected
dams (p=0.15). At day 3 of age, pups from uninfected dams
were separated into two groups and treated either three times
with toltrazuril (A, n=13) or three times with placebo (B, n=
6). Chemotherapy itself with three temporally sequential
applications of toltrazuril had no negative effect on the health
status and survival of the newborn pups, as the uninfected
control group (A) developed normally and showed no
spontaneous morbidity and mortality after the last treatment
until the end of the experiment.
Also at day 3 of age, pups from infected dams were
separated in four different groups and treated one or three
times with toltrazuril or placebo. When comparing the
proportion of surviving pups of different infected treatment
groups (C–F), significantly higher proportions were found for
toltrazuril-treated groups (Fig. 2). The proportion of surviving
three-time-toltrazuril-treated pups (D) was significantly
higher than the proportion of surviving three-time-placebo-
treated ones (F) (54% vs 30%; p=0.0072). A significant
difference in the proportion of surviving newborns was also
found between one-time-toltrazuril-treated (C) and one-time-
placebo-treated (E) pups (34% vs 14%; p<0.01). Similar
proportions of surviving pups were observed in the three-
time-placebo-treated (F) and one-time-toltrazuril-treated
groups (C). There was no significant difference between
the toltrazuril treatment groups C and D (p=0.2), but three-
time-toltrazuril treatment resulted in a 1.6 times higher
proportion of surviving pups compared to one-time-
toltrazuril treatment (Fig 2).
Outcome of the disease
The outcome of disease in very young diseased animals
was characterized by spontaneous death. Older pups
0.0
0.3
0.5
0.8
1.0
IgG1 IgG2a
A
[4
0
5
]
*
Fig. 1 Anti-N. caninum IgG isotype levels of infected dams as
determined by ELISA, sera were sampled at 33 dpi. There was a
significantly higher IgG2a level compared to IgG1 level in these
dams. *p<0.05; significance hold true
Table 1 Number of delivering dams and delivered newborns
Uninfected control
group
Infected
group
No. of delivering dams 3/3 21/21
Average pups per litter 8.6 (7, 10) 7.2 (3, 10)
Total no. of newbornsa 26 130
Died before treatmentb 0 8
Cannibalized during
experimentc
7 20
a Total number of live newborns at day 0 (day of birth)
b Number of pups that died before treatment, which started at day 3 of
age. Pups were signed as untreated pups
c Number of pups that were cannibalized by mothers before or after
treatment. These pups were logically excluded from the study because
examinations were not possible
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showed typical signs of murine neosporosis (apathy, bent
back, rough hair coat) and were euthanized at the time the
symptoms appeared.
Infected and placebo-treated pups (group E, n=19; group
F, n=16) died or became sick within the first 27 days after
birth. Most of infected and toltrazuril-treated pups (C, n=
19; D, n=13), on the other hand, started to die or to show
clinical signs from day 27 onwards (Fig. 3). This delay in
the outbreak of neosporosis was significant (p<0.01)
between toltrazuril-treated and placebo-treated groups but
not between the two toltrazuril-treated groups with different
application schemes.
Detection of N. caninum in congenitally infected
and treated mice
Detection of parasite DNA was performed by PCR
using DNA extracted from different organs of pups. The
transmission, calculated retrospectively, revealed a pro-
portion of vertical transmission of 74%. The proportion
of PCR-positive pups in placebo-treated groups (E, F)
ranged between 86% and 65%, whereas the proportion
of PCR-positive pups in toltrazuril-treated groups (C, D)
was between 66% and 47% (Table 2). There was a
significantly different number of PCR-positive pups in the
placebo-treated groups compared to the toltrazuril-treated
groups (p=0.03). There was no significant difference,
however, between one-time-toltrazuril-treated and three-
time-toltrazuril-treated pups (p=0.14). We observed that
those pups that became ill or died, independently of the
treatment scheme, all exhibited cerebral infection, as
determined by PCR.
Serological examination of congenitally infected mice
For serological studies, healthy pups killed at the end of the
experiment and pups prematurely killed because of illness
could be investigated. Pups that became ill during the
experiment showed significantly (p<0.01) higher IgG
levels than pups that survived until the end of the
experiment, independently of the treatment schedule
(Fig. 4a). As healthy pups exhibited negative or only very
low antibody levels, they were not included anymore for
further data analyses. Comparison of the IgG levels of only
diseased pups, taking into account the different treatment
groups, revealed a significantly higher antibody response
for three-time-toltrazuril-treated pups (D vs C, p=0.02; D
0 
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53 
70 
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a
g
e
 [
d
]
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treatment groups 
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Fig. 3 Outbreak of disease depended on the age of pups. Outbreak of
disease was defined when a pup died or became ill and was tested
positive by Neospora PCR. There was a significant difference in the
age when pups became ill between toltrazuril-treated and placebo-
treated pups. *p<0.05; significance hold true
Fig. 2 Proportion of surviving pups. Proportions were calculated with
Kaplan–Meier survival statistics. Untreated and cannibalized pups
were excluded. Pups that died or became ill during the experiment
were designated as failed, while healthy pups were designated as
censored. Statistical differences were calculated with log-rank survival
tests. Significant differences (*p<0.05) were found between the
proportion of surviving of one-time-toltrazuril-treated and one-time-
placebo-treated pups, as well as three-time-toltrazuril- and three-time-
placebo-treated pups. No significant differences were observed
between one-time-toltrazuril-treated and three-time-toltrazuril-treated
pups, and also none between three-time-placebo-treated and one-time-
toltrazuril-treated pups
Table 2 Proportion of PCR-positive pups in different treatment groups
1xPla (%) 3xPla (%) 1xTol (%) 3xTol (%)
PCR+ 86 65 64 47
PCR was performed with organs from pups that died or became ill
during the experiment as well as from pups that were still alive at the
end of the experiment. The age of the pups ranged between 0 and
100 days
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vs E, p=0.03) (Fig. 4b). We also determined the main IgG
subclasses of diseased pups involved in the anti-N. caninum
response. With regard to IgG1, there was no significant
difference in antibody levels between the different treat-
ment groups (p=0.08) (Fig. 4c). With regard to IgG2a,
there was a significantly higher respective antibody level in
group D when compared to group C (p=0.007) and group E
(p=0.03) (Fig. 4d). Finally, there were no significant
differences between IgG1 and IgG2a levels when compar-
ing the results of different treatment groups. Consequently,
this indicated that pups appeared to have mounted a mixed
Th1/Th2 immune response following an in utero infection,
independently of the treatment schedule subsequent to
delivery.
Pharmacokinetic analyses
Temporal pharmacokinetic parameters of toltrazuril resorp-
tion and respective plasma and tissue levels were assessed
using uninfected newborn mice (Fig. 5), which had been
treated as outlined in the infection experiments. In serum
samples and brain tissues, maximal toltrazuril concentra-
tions were found 2 to 3 days after the respective treatments
(Fig. 5a). Highest toltrazuril levels were observed 2 days
after the second toltrazuril application in both serum
samples (10.1 mg/L) and brain (9.2 mg/kg) tissues. After
reaching maximal values 2 to 3 days after drug application,
toltrazuril levels decreased until the next treatment. There
was no difference in toltrazuril concentration measured
between serum samples or brain tissues. Toltrazuril con-
centrations in serum samples and brain tissues were below
detection limit from day 8 after the third treatment onwards.
Newborn mice were able to metabolize toltrazuril, as the
major metabolite toltrazuril sulfone was found in serum
samples and brain tissues (Fig. 5b). Toltrazuril sulfone
accumulated after two applications of toltrazuril and
reached maximal concentration in serum samples
(18.5 mg/L) and brain tissues (9.0 mg/kg) 2 days after the
second treatment. Thereafter, the concentration decreased in
serum samples and brain tissues until the next treatment.
After the third toltrazuril application, maximal metabolite
concentrations were found 3 days later in serum samples
and brain tissues. Toltrazuril sulfone levels decreased
thereafter below detection limit at day 21 after the third
treatment. Over the whole time period, significantly higher
toltrazuril sulfone concentrations were observed in serum
samples when compared to the concentrations found in
brain tissues.
Discussion
To date, the main mode of control of neosporosis is based
upon culling persistently infected, seropositive reproducing
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Fig. 4 Antibody response of
pups from infected dams.
a Comparison of IgG levels
between pups that became ill
during the experiment and pups
that were healthy at the end of
the experiment. There was a
significant difference between
the two groups. b Comparison
of IgG levels between diseased
pups of different treatment
groups. There was a significant
difference between three-
time-toltrazuril-treated pups and
all other groups. c Comparison
of the IgG1 level between
diseased pups of different treat-
ment groups. There was no
difference between the two
treatment groups. d Comparison
of the IgG2a level between
diseased pups of different treat-
ment groups. There was a
significant difference between
three-time-toltrazuril-treated
pups and all other groups.
*p<0.05; significance hold true
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animals, as there is no effective treatment for cattle
available so far (Andrianarivo et al. 2000; Innes and
Vermeulen 2006). Toltrazuril is one of those few com-
pounds that have demonstrated antiparasitic activity against
N. caninum infections not only in cell culture-based assays,
but also in vivo as shown in experimentally infected mice
and even cattle (Darius et al. 2004a, b; Gottstein et al. 2001;
Gottstein et al. 2005; Kritzner et al. 2002; Härdi et al.
2006).
The present study was designed as a further step in
assessing the efficacy of toltrazuril by addressing the effect
of toltrazuril in congenitally N. caninum-infected newborn
mice. These experiments were intended to provide baseline
data upon use of a small animal model, prior to carrying out
similar experiments in the bovine system in the future.
Recently, cell culture assays had indicated that toltrazuril
required 14 days of in vitro treatment to yield parasiticidal
activity; short-time exposures did not kill all parasites
(Strohbusch et al. 2008). Extrapolating these findings to our
mouse model, we should anticipate an appropriate and
constant high toltrazuril concentration in vivo for at least
14 days; thus, repeated applications of toltrazuril seemed to
be necessary. Congenitally infected newborn mice were
treated with toltrazuril right after birth, either once or by
three treatments. Control analyses showed that three
consecutive control applications of toltrazuril alone (with-
out concurrent infection) had no negative effect on the
development and health status of newborns, thus justifying
a multiple administration of the drug. With regard to the
outcome of infection, both one and three toltrazuril
applications significantly delayed the outbreak of congen-
itally acquired neosporosis in newborn mice, as pups
treated once or three times with toltrazuril diseased at a
significantly later time point when compared to placebo-
treated pups. A marked delay of disease after toltrazuril
treatment had already been observed in N. caninum-
infected athymic nu−/nu− mice (Ammann et al. 2004), and
these experiments had indicated that toltrazuril had a
parasitostatic rather than a parasiticidal effect, requiring T
cell-mediated support to control neosporosis. In the present
study, the overall proportion of surviving animals in the
three-time-toltrazuril-treated group was 1.6 times higher
than the proportion of one-time-treated pups. Consequently,
one application of toltrazuril appeared not as effective as
repeated treatments. Similar findings were observed when
comparing the number of diseased pups or the number of N.
caninum PCR-positive pups. Both parameters were mark-
edly reduced in three-time-toltrazuril-treated group com-
pared to one-time-toltrazuril-treated and the placebo-treated
pups. Finally, we conclude from these findings that a
repeated toltrazuril application in newborn mice is manda-
tory to maintain an appropriate plasma and tissue level.
*
* *
*
*
*
*
*
Fig. 5 Pharmacokinetic of toltrazuril. Concentration of toltrazuril (a)
and its major metabolite toltrazuril sulfone (b) were evaluated over
time after three oral applications of toltrazuril. Measurements were
performed using serum samples (closed squares) and brain tissues
(open squares) of uninfected and treated newborn mice. Arrows
indicate day of treatment. *p<0.05; significance hold true
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This became best apparent when the three-time-placebo-
treated group yielded a proportion of surviving animals
similar to that of one-time-toltrazuril-treated mice. We can
only speculate why the three-time-placebo-treated group
performed better than the one-time-placebo-treated group:
intergroup variability may provide one explanation; another
one would be that the repeated exposure of mice to the
placebo may have supported nonspecific defense mecha-
nisms in favor of the mouse and in disadvantage of the
proliferating parasite.
It was shown earlier that newborn mice were as effective as
adults in developing primary antigen-specific T cell popula-
tions within the first week of life (Adkins and Du 1998) and
are thus fully immune competent at this age (Morein et al.
2002), although pathogen-specific immunity needs to be
primarily developed upon first contact with respective
organisms. Applied to our experiments, this allows the
conclusion that congenitally infected pups appeared to have
mounted a T cell immune response supporting toltrazuril
treatment effectively. Antibodies also play an important role
in the control of N. caninum infection, as B cell-deficient
(μMT) mice were highly susceptible to infection (Eperon et
al. 1999). Our data revealed that three-time-toltrazuril
treatment yielded the highest antibody responses in treated
pups. This is in line with the findings of Härdi et al. (2006),
who observed the development of a strong humoral immune
response after toltrazuril chemotherapy of congenitally
(naturally) infected calves (Härdi et al. 2006). Similar results
have also been documented in studies with Eimeria-infected
chicken where an increase of parasite-specific antibody
response after toltrazuril treatment was observed (Greif
2000).
Preliminary explorative experiments in cattle revealed
a half-life time of toltrazuril sulfone (ponazuril) in
serum samples of about 10 days (Kritzner et al. 2002).
Toltrazuril sulfone was detectable up to 47 days after one
application and up to 82 days after a 6-day treatment with
20 mg ponazuril per kg body weight. Pharmacokinetic
evaluation of toltrazuril performed in the present study
(unexpectedly) revealed that toltrazuril is much faster
metabolized in newborn mice than in calves. The reason
for this remains unclear. After three toltrazuril applications
within 24 days, toltrazuril and toltrazuril sulfone concen-
trations already dropped below the limit of quantitation of
8 and 21 days, respectively, after the last medication.
Furthermore, there was no accumulation of toltrazuril
between the three treatments, indicating that time intervals
between the application days may have been too long to
establish a constant high toltrazuril concentration over a
14-day time period. Nevertheless, evaluation of drug
concentration in brain tissues demonstrated for the first
time that toltrazuril and toltrazuril sulfone passed the
blood–brain barrier in mice. Similar findings were
observed after treatment of horses with toltrazuril (Furr
and Kennedy 2000).
The results presented in this study indicated that
treatment with three applications of toltrazuril had the best
positive effect to control the course of infection in
congenitally N. caninum-infected newborn mice. On the
other hand, we had to accept that both treatment schedules
did not yield a complete end-point elimination of the
parasite load. One explanation for this may have been the
fact that the toltrazuril levels did not remain constantly
high, as initially anticipated, but transiently dropped to low
levels within intervals of a few days. Consequently, future
studies will require a careful adaptation of the treatment
schedule, based on the pharmacokinetic results, to obtain
constant toltrazuril levels over a long time period. This
might then increase the proportion of surviving congenital-
ly infected newborn mice. Nevertheless, the present find-
ings will be useful to address the question of efficacy in the
experimental bovine model. Provided we can reach similar
or even improved levels of efficacy, then the final aim will
be to maturate an appropriate treatment schedule such as to
allow controlling the problem at a national level of bovine
production, anticipating a positive cost–benefit ratio as
claimed by Häsler et al. (2006a, b; 2008).
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